Literature DB >> 15470059

CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection.

Jane C Deng1, Thomas A Moore, Michael W Newstead, Xianying Zeng, Arthur M Krieg, Theodore J Standiford.   

Abstract

Bacterial pneumonia is a leading cause of mortality in the United States. Innate immune responses, including type-1 cytokine production, are critical to the effective clearance of bacterial pathogens from the lung. Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG dinucleotide motifs (CpG ODN), which mimic the effects of bacterial DNA, have been shown to enhance type-1 cytokine responses during infection due to intracellular pathogens, resulting in enhanced microbial clearance. The role of CpG ODN in modulating protective innate immunity against extracellular pathogens is unknown. Using a murine model of Gram-negative pneumonia, we found that CpG ODN administration stimulated protective immunity against Klebsiella pneumoniae. Specifically, intratracheal (i.t.) administration of CpG ODN (30 microg) 48 h before i.t. K. pneumoniae challenge resulted in increased survival, compared with animals pretreated with control ODN or saline. Pretreatment with CpG ODN resulted in enhanced bacterial clearance in lung and blood, and higher numbers of pulmonary neutrophils, NKT cells, gammadelta-T cells, and activated NK1.1+ cells and gammadelta-T lymphocytes during infection. Furthermore, pretreatment with CpG ODN enhanced the production of TNF-alpha, and type-1 cytokines, including IL-12, IFN-gamma, and the IFN-gamma-dependent ELR- CXC chemokines IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma in response to Klebsiella challenge, compared with control mice. These findings indicate that i.t. administration of CpG ODN can stimulate multiple components of innate immunity in the lung, and may form the basis for novel therapies directed at enhancing protective immune responses to severe bacterial infections of the lung.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15470059      PMCID: PMC3001228          DOI: 10.4049/jimmunol.173.8.5148

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  Bacterial DNA causes septic shock.

Authors:  T Sparwasser; T Miethke; G Lipford; K Borschert; H Häcker; K Heeg; H Wagner
Journal:  Nature       Date:  1997-03-27       Impact factor: 49.962

2.  Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma.

Authors:  J N Kline; T J Waldschmidt; T R Businga; J E Lemish; J V Weinstock; P S Thorne; A M Krieg
Journal:  J Immunol       Date:  1998-03-15       Impact factor: 5.422

3.  Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock.

Authors:  T Sparwasser; T Miethke; G Lipford; A Erdmann; H Häcker; K Heeg; H Wagner
Journal:  Eur J Immunol       Date:  1997-07       Impact factor: 5.532

4.  Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12.

Authors:  J H Chace; N A Hooker; K L Mildenstein; A M Krieg; J S Cowdery
Journal:  Clin Immunol Immunopathol       Date:  1997-08

5.  Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.

Authors:  Z K Ballas; W L Rasmussen; A M Krieg
Journal:  J Immunol       Date:  1996-09-01       Impact factor: 5.422

6.  Macrophages ingest and are activated by bacterial DNA.

Authors:  K J Stacey; M J Sweet; D A Hume
Journal:  J Immunol       Date:  1996-09-01       Impact factor: 5.422

7.  IL-12 gene therapy protects mice in lethal Klebsiella pneumonia.

Authors:  M J Greenberger; S L Kunkel; R M Strieter; N W Lukacs; J Bramson; J Gauldie; F L Graham; M Hitt; J M Danforth; T J Standiford
Journal:  J Immunol       Date:  1996-10-01       Impact factor: 5.422

8.  Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides.

Authors:  J S Cowdery; J H Chace; A K Yi; A M Krieg
Journal:  J Immunol       Date:  1996-06-15       Impact factor: 5.422

9.  Control of natural killer cell-mediated innate resistance against the intracellular pathogen Listeria monocytogenes by gamma/delta T lymphocytes.

Authors:  C H Ladel; C Blum; S H Kaufmann
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

10.  CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.

Authors:  R S Chu; O S Targoni; A M Krieg; P V Lehmann; C V Harding
Journal:  J Exp Med       Date:  1997-11-17       Impact factor: 14.307

View more
  38 in total

Review 1.  Innate Immune Signaling Activated by MDR Bacteria in the Airway.

Authors:  Dane Parker; Danielle Ahn; Taylor Cohen; Alice Prince
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

2.  CpG-oligodeoxynucleotide is a potent adjuvant with an Entamoeba histolytica Gal-inhibitable lectin vaccine against amoebic liver abscess in gerbils.

Authors:  Catherine P A Ivory; Kathy Keller; Kris Chadee
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Allergic airway inflammation decreases lung bacterial burden following acute Klebsiella pneumoniae infection in a neutrophil- and CCL8-dependent manner.

Authors:  Daniel E Dulek; Dawn C Newcomb; Kasia Goleniewska; Jaqueline Cephus; Weisong Zhou; Sara Reiss; Shinji Toki; Fei Ye; Rinat Zaynagetdinov; Taylor P Sherrill; Timothy S Blackwell; Martin L Moore; Kelli L Boyd; Jay K Kolls; R Stokes Peebles
Journal:  Infect Immun       Date:  2014-06-23       Impact factor: 3.441

Review 4.  Inhaled innate immune ligands to prevent pneumonia.

Authors:  Scott E Evans; Michael J Tuvim; Cory J Fox; Nidhi Sachdev; Leonid Gibiansky; Burton F Dickey
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

5.  Cationic liposomes extend the immunostimulatory effect of CpG oligodeoxynucleotide against Burkholderia pseudomallei infection in BALB/c mice.

Authors:  Apichaya Puangpetch; Robert Anderson; Yan Y Huang; Rasana W Sermswan; Wanpen Chaicumpa; Stitaya Sirisinha; Surasakdi Wongratanacheewin
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

Review 6.  Vaccine approaches for multidrug resistant Gram negative infections.

Authors:  Brian Campfield; Kong Chen; Jay K Kolls
Journal:  Curr Opin Immunol       Date:  2014-03-15       Impact factor: 7.486

7.  A novel gonorrhea vaccine composed of MetQ lipoprotein formulated with CpG shortens experimental murine infection.

Authors:  Aleksandra E Sikora; Carolina Gomez; Adriana Le Van; Benjamin I Baarda; Stephen Darnell; Fabian G Martinez; Ryszard A Zielke; Josephine A Bonventre; Ann E Jerse
Journal:  Vaccine       Date:  2020-11-05       Impact factor: 3.641

8.  Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice.

Authors:  Cecilia G Clement; Scott E Evans; Christopher M Evans; David Hawke; Ryuji Kobayashi; Paul R Reynolds; Seyed J Moghaddam; Brenton L Scott; Ernestina Melicoff; Roberto Adachi; Burton F Dickey; Michael J Tuvim
Journal:  Am J Respir Crit Care Med       Date:  2008-04-03       Impact factor: 21.405

9.  Cooperative interactions between TLR4 and TLR9 regulate interleukin 23 and 17 production in a murine model of gram negative bacterial pneumonia.

Authors:  Urvashi Bhan; Megan N Ballinger; Xianying Zeng; Michael J Newstead; Matthew D Cornicelli; Theodore J Standiford
Journal:  PLoS One       Date:  2010-03-26       Impact factor: 3.240

10.  Intratracheal synthetic CpG oligodeoxynucleotide causes acute lung injury with systemic inflammatory response.

Authors:  Sadatomo Tasaka; Hirofumi Kamata; Keisuke Miyamoto; Yasushi Nakano; Hiromi Shinoda; Yoshifumi Kimizuka; Hiroshi Fujiwara; Naoki Hasegawa; Seitaro Fujishima; Taku Miyasho; Akitoshi Ishizaka
Journal:  Respir Res       Date:  2009-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.